Immunovia
0.25 SEK
-4.25 %
Less than 1K followers
IMMNOV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-4.25 %
-21.52 %
-46.21 %
-28.41 %
-41.58 %
-54.04 %
-97.61 %
-99.44 %
-97.67 %
Immunovia operates in the biotechnology industry and focuses on the development of diagnostic tools for the early detection of cancer. The company's research and development is focused on molecular diagnostics and its products are aimed at healthcare institutions and physicians. The business is global with a strong presence in Europe and North America. Immunovia was founded in 2007 and is headquartered in Lund.
Read moreMarket cap
166.82M SEK
Turnover
1.05M SEK
Revenue
930K
EBIT %
-11,764.52 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
24/2
2026
Annual report '25
7/5
2026
Interim report Q1'26
15/5
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
NOTICE OF EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)
Styrelsen för Immunovia föreslår en sammanläggning av aktier
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools